Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · IEX Real-Time Price · USD
40.14
+1.49 (3.86%)
May 31, 2024, 4:00 PM EDT - Market closed
Ultragenyx Pharmaceutical Employees
Ultragenyx Pharmaceutical had 1,276 employees on December 31, 2023. The number of employees decreased by 35 or -2.67% compared to the previous year.
Employees
1,276
Change (1Y)
-35
Growth (1Y)
-2.67%
Revenue / Employee
$346,854
Profits / Employee
-$480,683
Market Cap
3.34B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,276 | -35 | -2.67% |
Dec 31, 2022 | 1,311 | 192 | 17.16% |
Dec 31, 2021 | 1,119 | 226 | 25.31% |
Dec 31, 2020 | 893 | 153 | 20.68% |
Dec 31, 2019 | 740 | 130 | 21.31% |
Dec 31, 2018 | 610 | 90 | 17.31% |
Dec 31, 2017 | 520 | 144 | 38.30% |
Dec 31, 2016 | 376 | 127 | 51.00% |
Dec 31, 2015 | 249 | 142 | 132.71% |
Dec 31, 2014 | 107 | 48 | 81.36% |
Dec 31, 2013 | 59 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Surgery Partners | 13,500 |
Envista Holdings | 12,800 |
LivaNova | 2,900 |
Tandem Diabetes Care | 2,400 |
HUTCHMED (China) | 1,988 |
Guardant Health | 1,779 |
Axonics | 797 |
PROCEPT BioRobotics | 626 |
RARE News
- 1 day ago - Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) - GlobeNewsWire
- 14 days ago - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 24 days ago - Ultragenyx to Participate at Bank of America's 2024 Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update - GlobeNewsWire
- 4 weeks ago - Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease - GlobeNewsWire
- 5 weeks ago - Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update - GlobeNewsWire
- 7 weeks ago - Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome - GlobeNewsWire
- 7 weeks ago - Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting - GlobeNewsWire